NanoViricides President Discusses Broad-Spectrum Antiviral Platform and Upcoming Clinical Trials

NanoViricides, Inc. announced that President Dr. Anil R. Diwan discussed the company's mission to revolutionize antiviral treatment through its nanoviricide platform during an interview on the Mission Matters Podcast. Dr. Diwan explained how nanoviricides are engineered to prevent viral escape and function independently of patient immune status, offering broad-spectrum potential across diverse patient populations from infants to geriatrics.

The company's lead drug candidate, NV-387, has demonstrated efficacy against multiple unrelated viruses in lethal animal models, including Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles. According to Dr. Diwan, NV-387 has completed a Phase I clinical trial with no reported adverse events, and a Phase II clinical trial targeting MPox is ready to begin in the Democratic Republic of Congo following regulatory clearance. This positions NV-387 as a potential empirical therapy for acute respiratory and other viral infections with an estimated market opportunity exceeding $17 billion by 2030.

NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. as detailed on their website at https://www.nanoviricides.com. The company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

The company's platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of numerous human viral diseases including Human Immunodeficiency Virus, Hepatitis B and C viruses, Rabies, Herpes Simplex Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, and certain Coronaviruses. The company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if initial research is successful.

As with any drug development efforts, there can be no assurance at this time that any of the company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. The path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. Further, there can be no assurance that successful results against coronavirus in laboratory settings will lead to successful clinical trials or a successful pharmaceutical product. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.